Condition
Severe Acute Respiratory Distress Syndrome
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Completed2
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04370834Phase 2Terminated
Tocilizumab for Patients With Cancer and COVID-19 Disease
NCT04031794UnknownPrimary
ECMO for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure
NCT04333368Phase 1Completed
Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS
NCT00646152Phase 1Completed
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
Showing all 4 trials